Hospitalization rates before and after initiation of paliperidone ER in patients with schizophrenia: results from open-label extensions of the US double-blind trials

References

• American Psychiatric Association: Practice Guideline for the Treatment of Patients With Schizophrenia, 2nd edn. Arlington, VA, American Psychiatric Association, 2004
   Google Scholar
• Diagnostic and Statistical Manual of Mental Disorders: DSM–IV, 4th edn. Washington, DC, American Psychiatric Association, 1994
   Google Scholar
• Lieberman JA. Prediction of outcome in first-episode schizophrenia. J Clin Psychiatry 1999; V54(Suppl 3):13–17
   Google Scholar
• Regier DA, Narrow WE, Rae DS, . The de Facto US Mental and Addictive Disorder Service System, epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry 1993; 50:85–94
   PubMed Web of Science ®Google Scholar
• Wu EQ, Birnbaum HG, Shi L, . The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 2005; 66:1122–9
   PubMed Web of Science ®Google Scholar
• Rabinowitz J, Lichtenberg P, Kaplan Z, . Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158:266–9
   PubMed Web of Science ®Google Scholar
• Patel NC, Dorson PG, Edwards N, . One-year rehospitalization rates of patients discharged on atypical versus conventional antipsychotics. Psychiatr Serv 2002; 53:891–3
   PubMed Web of Science ®Google Scholar
• Conley RR, Kelly DL, Love RC, . Rehospitalization risk with second generation and depot antipsychotics. Ann Clin Psychiatry 2003; 15:23–31
   PubMedGoogle Scholar
• McDonald M, Hertz RP, Lustik MB, . Healthcare spending among community-dwelling adults with schizophrenia. Am J Manage Care 2005; 11:S242–7
   Google Scholar
• Marder SR, Kramer M, Ford L, . Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 2007; 00Epub ahead of print
   Google Scholar
• Kane J, Canas F, Kramer M, . Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147–61
   PubMed Web of Science ®Google Scholar
• Davidson M, Emsley R, Kramer M, . Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 2007; 93:117–30
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13:261–76
   PubMed Web of Science ®Google Scholar
• Kay S, Opler L, Fizbein A. The Positive and Negative Syndrome Scale (PANSS) Manual. North Tohawanda, NY, Multi-Health System, 1986
   Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997; 58:538–46
   PubMed Web of Science ®Google Scholar
• Morosini PL, Magliano L, Brambilla L, . Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 2000; 101:323–9
   PubMed Web of Science ®Google Scholar
• Gagnon D, Nasrallah H, Morosini PL. The personal and social performance scale: reliability, validity, and ability to detect changes in patients with acute schizophreniaPoster session presented at the annual meeting of the American Psychiatry AssociationToronto, Canada 2006
   Google Scholar
• Patrick DL, Morosini PL, Rothman M. The personal and social performance scale: measuring functional improvement in outpatients with stable schizophreniaPoster session presented at the annual meeting of the American Psychiatry AssociationToronto, Canada 2006
   Google Scholar
• Meltzer H, Kramer M, Gassmann-Mayer C, . Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week placebo controlled studies. Int J Neuropsychopharmacol 2006; 9(Suppl 1):S226
   Google Scholar
• Eerdekens M, Kramer M, Lane R, . Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week, open-label extension studiesPoster presented at International Congress on Schizophrenia ResearchColorado, USA 2007 28–1 April 2007, Poster number 290
   Google Scholar
• Kramer M, Kushner S, Vijapurkar U. Paliperidone extended-release tablets for prevention of symptoms recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychopharmacol. 2007; 27:6–14
   Google Scholar
• National Institute of Mental Health. 028 CGI clinical global impressions. ECD-EU Assessment for Psychopharmacology, Rev edn. In Guy W ed. Rockville, MD, National Institute of Mental Health, 1976:217–22
   Google Scholar
• Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008; 34:173–80
   PubMed Web of Science ®Google Scholar